NCT07509307 (AMAZE 6) is a Phase 3 clinical trial of NNC0487-0111 in Obesity, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT07509307?

NCT07509307 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT07509307?

Interventions in NCT07509307: NNC0487-0111, Placebo (matched to NNC0487-0111).

What condition does NCT07509307 study?

NCT07509307 studies Obesity, Overweight, Osteoarthritis, Knee.

Is NCT07509307 still recruiting?

NCT07509307 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT07509307: AMAZE 6

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Recruiting now Phase 3 Last updated 3 April 2026

What this trial tests

Phase 3 trial testing NNC0487-0111 in Obesity in 400 participants. Currently enrolling.

Timeline

20 April 2026

Primary endpoint
19 June 2028

14 August 2028

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	400
Start date	20 April 2026
Primary completion	19 June 2028
Estimated completion	14 August 2028
Sites	78 locations across Puerto Rico, Greece, Spain, Bulgaria, Australia, Poland, United States, Canada

Drugs / interventions tested

NNC0487-0111 — full drug profile →
Placebo (matched to NNC0487-0111) — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →
Osteoarthritis, Knee — all drugs for Osteoarthritis, Knee →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

18 and older, any sex, with Obesity or Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of NNC0487-0111

Trials testing the same drug.

NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
NCT07503210 — AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintai · Phase 3 · not yet recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07533175 — AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type · Phase 3 · not yet recruiting
NCT07535307 — Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes · Phase 1 · not yet recruiting

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
NCT07062094 — Safety and Effectiveness of Orbera365™ Intragastric Balloon System · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07509307 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07509307.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing